Worth reading
44Recurring
Scored from 1 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
0
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Second and Third Series of Stock Acquisition Rights issued through a third-party allotment (with conversion rights to stock acquisition rights with exercise price adjustments)
Terms of the stock acquisition rights
Exercise price
¥550 for the Series 2 warrants and ¥600 for the Series 3 warrants. The Company's Board of Directors has not resolved to convert the warrants to exercise-price-adjustable warrants, and the exercise prices have not been adjusted. The lower limit for any adjustment is not disclosed.
Number of Stock Acquisition Rights
Series 2 warrants: total number issued, not disclosed; unexercised balance at the end of the reporting month, 4,500 warrants. Series 3 warrants: total number issued, not disclosed; unexercised balance at the end of the reporting month, 4,500 warrants.
Procedures under the Corporate Code of Conduct
The exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc. are described. However, because no resolution has been made to exercise the conversion rights and the exercise prices have not been adjusted, there are no exercise restrictions.
Most recent equity financing
4 January 2024: Issuance of Series 2 and Series 3 warrants through third-party allotment. Amount: not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Second and Third Series of Stock Acquisition Rights issued through a third-party allotment (with conversion rights to stock acquisition rights with exercise price adjustments) |
| Total number of issued shares | 21,618,800 shares (as of the end of the month preceding the reporting month) → Not disclosed |
| Exercise price | ¥550 for the Series 2 warrants and ¥600 for the Series 3 warrants. The Company's Board of Directors has not resolved to convert the warrants to exercise-price-adjustable warrants, and the exercise prices have not been adjusted. The lower limit for any adjustment is not disclosed. |
| Number of Stock Acquisition Rights | Series 2 warrants: total number issued, not disclosed; unexercised balance at the end of the reporting month, 4,500 warrants. Series 3 warrants: total number issued, not disclosed; unexercised balance at the end of the reporting month, 4,500 warrants. |
| Procedures under the Corporate Code of Conduct | The exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc. are described. However, because no resolution has been made to exercise the conversion rights and the exercise prices have not been adjusted, there are no exercise restrictions. |
| Most recent equity financing | 4 January 2024: Issuance of Series 2 and Series 3 warrants through third-party allotment. Amount: not disclosed. |
Items this document does not state (22)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the Company's Board of Directors has not resolved to exercise the conversion rights to exercise-price-adjustable warrants, the exercise prices have not been adjusted. Neither the Series 2 nor Series 3 warrants was exercised in August 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.